Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
Summary: The immune-genetic changes sten jacket m that occur in cancer patients experiencing hyperprogressive disease (HPD) during combined immunotherapy are unclear.In this study, HPD patients with pre- and post-HPD samples and non-HPD patients with solid tumors were molecularly characterized by genetic and tumor immune microenvironment (TiME) ana